Genome Study Reveals Two Distinct Biological Depressions

Depression may wear two very different faces. One shows up tired and heavy. The other is restless and lean. Which one you get could be written in your genes.

Major depressive disorder, a clinical form of depression, is not just a mood swing. It is a disabling illness that touches roughly one in ten people in the United States over a lifetime and costs the economy hundreds of billions in health care and lost work. Yet for decades clinicians have lumped opposite symptoms together. Feeling sleepy and gaining weight or losing sleep and losing weight both score toward the same diagnosis. That simplification has helped clinicians talk to one another. But it may have obscured how different the biology can be beneath a shared label.

A new genetic analysis, reported as a preprint and not yet peer reviewed, pushes back on that one-size-fits-all view. Researchers parsed major depressive disorder by focusing on energy related symptoms that run in opposite directions: hypersomnia with weight gain, labeled AERS+, and insomnia with weight loss, labeled AERS-. A third, intermediate group they called Uncategorized showed a blend of features. Then the team went hunting for genetic signals across more than 460,000 people of European ancestry.

The results read like a split clinical playbook. AERS+ tilts toward higher body mass index, earlier onset and worse functional impairment. People in this group also carry a heavier burden of other medical conditions. AERS-, by contrast, associates with metabolic traits that often look more favorable on the surface, such as smaller waist circumference and a lower genetic risk for type 2 diabetes, but it is not a benign profile. Each subtype appears to follow different biological routes.

Across the three subtypes the researchers identified 27 genomic loci linked to symptom patterns. Four loci were tied to AERS+, including a locus previously connected to body mass index and depression, and a non coding RNA linked to cortical inhibitory neurons, the cells that quiet activity in neural circuits. Ten loci mapped to AERS-, some of which relate to gene regulation patterns that overlap with schizophrenia and with traits associated with leanness. The remaining 13 loci characterized the Uncategorized group, which genetically sits between the two extremes but is not simply a mixture of them.

Curiously, the genetic fingerprints point to different neural players. AERS+ variants align more with inhibitory neurons, while AERS- variants show links to excitatory neurons, the cells that drive activity. That neural split resonates with the opposing symptom directions: sleepiness versus insomnia, appetite increase versus loss. It suggests that the same diagnostic label may conceal distinct brain circuit dynamics.

Metabolism and inflammation also play a starring role. AERS+ shows a positive genetic correlation with five metabolic markers: body mass index, waist circumference, metabolic syndrome, type 2 diabetes, and blood glucose. It correlates negatively with protective HDL cholesterol and positively with C reactive protein, a circulating marker of inflammation. The picture is one of impaired cholesterol transport, insulin resistance, and a pro inflammatory state that raises vascular risk. In short, AERS+ looks genetically like someone on the trajectory toward metabolic syndrome. AERS- trends in the opposite direction.

So what does all this mean for patients and treatment? If depression comes in biologically distinct flavors, then a treatment that helps one person might fail another because it is aimed at a different underlying pathway. Are immunometabolic processes driving symptoms, or are they modifiers that shape how depression appears? The answer is not settled, but either possibility changes how researchers should design studies and how clinicians might personalize care.

This work reframes major depressive disorder as a set of overlapping but biologically distinct entities rather than a single, uniform disease.

The study is a preprint, and its findings need replication and clinical follow up. Still, the message is clear: paying attention to appetite, weight and sleep patterns may reveal a deeper biological logic in depression. The next steps will test whether metabolic and inflammatory pathways can be targeted to prevent the downstream cascade, or whether they are signposts that help match patients to the right therapy. Either way, the era of one-size-fits-all psychiatry may be numbered.